Factors influencing late allograft valve failure

Scandinavian Cardiovascular Journal

Volumn 38, Issue 6, 2004, Pages 325-333

  Yap, Cheng Hon ^a,b   Yii, Michael ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b GEELONG HOSPITAL   (Australia)

Author keywords

Allograft; Aortic valve; Heart valve surgery; Immunology; Pulmonary valve

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTEGRIN MONOCLONAL ANTIBODY; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTIGEN EXPRESSION; ANTIGENICITY; BLOOD COMPATIBILITY; CELL VIABILITY; CONGENITAL HEART DISEASE; CRYOPRESERVATION; DONOR; FREEZE DRYING; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART HEMOSIDEROSIS; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VALVE REPLACEMENT; HLA MATCHING; HUMAN; IMMUNE RESPONSE; INFECTION; IRRADIATION; ISCHEMIA; LONG TERM CARE; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECIPIENT; REOPERATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL TECHNIQUE; TISSUE ENGINEERING; TISSUE PRESERVATION; VALVULAR HEART DISEASE;

AORTIC VALVE; GRAFT SURVIVAL; HEART VALVE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PULMONARY VALVE; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTS; TREATMENT FAILURE;

EID: 12344265536     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430410016387     Document Type: Review

References (93)

1. Lund O, Chandrasekaran V, Grocott-Mason R, et al. Primary aortic valve replacement with allografts over twenty-five years: Valve-related and procedure-related determinants of outcome. J Thorac Cardiovasc Surg 1999; 117: 77-90.
2. O'Brien MF, Harrocks S, Stafford EG, et al. The homograft aortic valve: A 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis 2001; 10: 334-344.
3. Chambers JC, Somerville J, Stone S, Ross DN. Pulmonary autograft procedure for aortic valve disease: Long-term results of the pioneer series. Circulation 1997; 96: 2206-2214.
4. Eriksson MJ, Kallner G, Rosfors S, Ivert T, Brodin LA. Hemodynamic performance of cryopreserved aortic homograft valves during midterm follow-up. J Am Coll Cardiol 1998; 32: 1002-1008.
5. Hasegawa J, Kitamura S, Taniguchi S, et al. Comparative rest and exercise hemodynamics of allograft and prosthetic valves in the aortic position. Ann Thorac Surg 1997; 64: 1753-1756.
6. Niwaya K, Knott-Craig CJ, Santangelo K, Lane MM, Chandrasekaran K, Elkins RC. Advantage of autograft and homograft valve replacement for complex aortic valve endocarditis. Ann Thorac Surg 1999; 67: 1603-1608.
7. Sabik JF, Lytle BW, Blackstone EH, Martillo AG, Pettersson GB, Cosgrove DM. Aortic root replacement with cryopreserved allograft for prosthetic valve endocarditis. Ann Thorac Surg 2002; 74: 650-659; discussion 659.
8. Barratt-Boyes BG, Roche AH, Subramanyan R, Pemberton JR, Whitlock RM. Long-term follow-up of patients with the antibiotic-sterilized aortic homograft valve inserted freehand in the aortic position. Circulation 1987; 75: 768-777.
9. Yacoub M, Rasmi NR, Sundt TM, et al. Fourteen-year experience with homovital homografts for aortic valve replacement. J Thorac Cardiovasc Surg 1995; 110: 186-193; discussion 193-194.
10. Takkenberg JJ, van Herwerden LA, Eijkemans MJ, Bekkers JA, Bogers AJ. Evolution of allograft aortic valve replacement over 13 years: Results of 275 procedures. Eur J Cardiothorac Surg 2002; 21: 683-691; discussion 691.
11. Palka P, Harrocks S, Lange A, Burstow DJ, O'Brien MF. Primary aortic valve replacement with cryopreserved aortic allograft: An echocardiographic follow-up study of 570 patients. Circulation 2002; 105: 61-66.
12. Langley SM, Livesey SA, Tsang VT, et al. Long-term results of valve replacement using antibiotic-sterilised homografts in the aortic position. Eur J Cardiothorac Surg 1996; 10: 1097-1105.
13. Kirklin JK, Smith D, Novick W, et al. Long-term function of cryopreserved aortic homografts. A ten-year study. J Thorac Cardiovasc Surg 1993; 106: 154-165; discussion 165-166.
14. Gerestein CG, Takkenberg H, Oei FB, et al. Right ventricular outflow tract reconstruction with an allograft conduit. Ann Thorac Surg 2001; 71: 911-918.
15. Willems TP, Takkenberg JJ, Steyerberg EW, et al. Human tissue valves in aortic position: Determinants of reoperation and valve regurgitation. Circulation 2001; 103: 1515-1521.
16. Schorn K, Yankah AC, Alexi-Meskhishvili V, Weng Y, Lange PE, Hetzer R. Risk factors for early degeneration of allografts in pulmonary circulation. Eur J Cardiothorac Surg 1997; 11: 62-69.
17. Baskett RJ, Nanton MA, Warren AE, Ross DB. Human leukocyte antien-DR and ABO mismatch are associated with accelerated homograft valve failure in children: Implications for therapeutic interventions. J Thorac Cardiovasc Surg 2003; 126: 232-239.
18. Albert JD, Bishop DA, Fullerton DA, Campbell DN, Clarke DR. Conduit reconstruction of the right ventricular outflow tract. Lessons learned in a twelve-year experience. J Thorac Cardiovasc Surg 1993; 106: 228-235; discussion 235-236.
19. Bando K, Danielson GK, Schaff HV, Mair DD, Julsrud PR, Puga FJ. Outcome of pulmonary and aortic homografts for right ventricular outflow tract reconstruction. J Thorac Cardiovasc Surg 1995; 109: 509-517; discussion 517-518.
20. Tweddell JS, Pelech AN, Frommelt PC, et al. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circulation 2000; 102: III130-III135.
21. Niwaya K, Knott-Craig CJ, Lane MM, Chandrasekaren K, Overholt ED, Elkins RC. Cryopreserved homograft valves in the pulmonary position: Risk analysis for intermediate-term failure. J Thorac Cardiovasc Surg 1999; 117: 141-146; discussion 146-147.
22. Daenen W, Gewillig M. Factors influencing medium-term performance of right-sided cryopreserved homografts. J Heart Valve Dis 1997; 6: 347-354.
23. Forbess JM, Shah AS, St Louis JD, Jaggers JJ, Ungerleider RM. Cryopreserved homografts in the pulmonary position: Determinants of durability. Ann Thorac Surg 2001; 71: 54-59; discussion 59-60.
24. Fann JI, Miller DC, Moore KA, et al. Twenty-year clinical experience with porcine bioprostheses. Ann Thorac Surg 1996; 62: 1301-1311.
25. Frater RW, Furlong P, Cosgrove DM, et al. Long-term durability and patient functional status of the Carpentier-Edwards Perimount pericardial bioprosthesis in the aortic position. J Heart Valve Dis 1998; 7: 48-53.
26. Clarke DR, Campbell DN, Hayward AR, Bishop DA. Degeneration of aortic valve allografts in young recipients. J Thorac Cardiovasc Surg 1993; 105: 934-941; discussion 941-942.
27. Ross DN. Evolution of the homograft valve. Ann Thorac Surg 1995; 59: 565-567.
28. Stark J, Bull C, Stajevic M, Jothi M, Elliott M, de Leval M. Fate of subpulmonary homograft conduits: Determinants of late homograft failure. J Thorac Cardiovasc Surg 1998; 115: 506-514; discussion 514-516.
29. Niwaya K, Sakaguchi H, Kawachi K, Kitamura S. Effect of warm ischemia and cryopreservation on cell viability of human allograft valves. Ann Thorac Surg 1995; 60: S114-S117.
30. Kadoba K, Armiger LC, Sawatari K, Jonas RA. Mechanical durability of pulmonary allograft conduits at systemic pressure. Angiographic and histologic study in lambs. J Thorac Cardiovasc Surg 1993; 105: 132-141.
31. DeLeon SY, Tuchek JM, Bell TJ, et al. Early pulmonary homograft failure from dilatation due to distal pulmonary artery stenosis. Ann Thorac Surg 1996; 61: 234-236; discussion 236-237.
32. O'Brien MF, McGiffin DC, Stafford EG. Allograft aortic valve implantation: Techniques for all types of aortic valve and root pathology. Ann Thorac Surg 1989; 48: 600-609.
33. Rubay JE, Raphael D, Sluysmans T, et al. Aortic valve replacement with allograft/autograft: Subcoronary versus intraluminal cylinder or root. Ann Thorac Surg 1995; 60: S78-S82.
34. Jones EL, Shah VB, Shanewise JS, et al. Should the freehand allograft be abandoned as a reliable alternative for aortic valve replacement? Ann Thorac Surg 1995; 59: 1397-1403; discussion 1403-1404.
35. Elkins RC. The Ross operation: A 12-year experience. Ann Thorac Surg 1999; 68: S14-S18.
36. Willems TP, van Herwerden LA, Steyerberg EW, et al. Subcoronary implantation or aortic root replacement for human tissue valves: Sufficient data to prefer either technique? Ann Thorac Surg 1995; 60: S83-S86.
37. Jones EL. Freehand homograft aortic valve replacement-the learning curve: A technical analysis of the first 31 patients. Ann Thorac Surg 1989; 48: 26-32.
38. Dignan R, O'Brien M, Hogan P, et al. Influence of HLA matching and associated factors on aortic valve homograft function. J Heart Valve Dis 2000; 9: 504-511.
39. Penta A, Qureshi S, Radley-Smith R, Yacoub MH. Patient status 10 or more years after 'fresh' homograft replacement of the aortic valve. Circulation 1984; 70: I182-I186.
40. Gall KL, Smith SE, Willmette CA, O'Brien MF. Allograft heart valve viability and valve-processing variables. Ann Thorac Surg 1998; 65: 1032-1038.
41. O'Brien MF, Stafford G, Gardner M, et al. The viable cryopreserved allograft aortic valve. J Card Surg 1987; 2: 153-167.
42. Lang SJ, Giordano MS, Cardon-Cardo C, Summers BD, Staiano-Coico L, Hajjar DP. Biochemical and cellular characterization of cardiac valve tissue after cryopreservation or antibiotic preservation. J Thorac Cardiovasc Surg 1994; 108: 63-67.
43. O'Brien MF, Stafford EG, Gardner MA, Pohlner PG, McGiffin DC. A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves, with a note on chromosomal studies. J Thorac Cardiovasc Surg 1987; 94: 812-823.
44. Albertucci M. Aortic valvular allografts and pulmonary autografts. In: Edmunds LH, editor. Cardiac surgery in the adult. 1st ed. New York: McGraw-Hill Professional, 1997.
45. Angell WW, Angell JD, Oury JH, Lamberti JJ, Grehl TM. Long-term follow-up of viable frozen aortic homografts. A viable homograft valve bank. J Thorac Cardiovasc Surg 1987; 93: 815-822.
46. O'Brien MF, Johnston N, Stafford G, et al. A study of the cells in the explanted viable cryopreserved allograft valve. J Card Surg 1988; 3: 279-287.
47. Koolbergen DR, Hazekamp MG, de Heer E, et al. The pathology of fresh and cryopreserved homograft heart valves: An analysis of forty explanted homograft valves. J Thorac Cardiovasc Surg 2002; 124: 689-697.
48. Mitchell RN, Jonas RA, Schoen FJ. Pathology of explanted cryopreserved allograft heart valves: Comparison with aortic valves from orthotopic heart transplants. J Thorac Cardiovasc Surg 1998; 115: 118-127.
49. Mitchell RN, Jonas RA, Schoen FJ. Structure-function correlations in cryopreserved allograft cardiac valves. Ann Thorac Surg 1995; 60: S108-S112; discussion S113.
50. Koolbergen DR, Hazekamp MG, Kurvers M, et al. Tissue chimerism in human cryopreserved homograft valve explants demonstrated by in situ hybridization. Ann Thorac Surg 1998; 66: S225-S232.
51. Gonzalez-Lavin L, Spotnitz AJ, Mackenzic JW, et al. Homograft valve durability: Host or donor influence? Heart Vessels 1990; 5: 102-106.
52. Smith JD, Rose ML, Pomerance A, Burke M, Yacoub MH. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet 1995; 346: 1318-1322.
53. Opelz G, Wujciak T. The Collaborative Transplant Study. The influence of HLA compatibility on graft survival after heart transplantation. N Engl J Med 1994; 330: 816-819.
54. Smith JD, Danskine AJ, Rose ML, Yacoub MH. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation 1992; 53: 1358-1362.
55. Leech SH, Mather PJ, Eisen HJ, et al. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function. Clin Transplant 1996; 10: 639-645.
56. Hoekstra F, Knoop C, Jutte N, et al. Effect of cryopreservation and HLA-DR matching on the cellular immunogenicity of human cardiac valve allografts. J Heart Lung Transplant 1993; 13: 1095-1098.
57. Hoekstra F, Knoop C, Aghai Z, et al. Stimulation of immune-competent cells in vitro by human cardiac valve-derived endothelial cells. Ann Thorac Surg 1995; 60: S131-S133; discussion S133-S134.
58. Hoekstra F, Knoop C, Vaessen L, et al. Donor-specific cellular immune response against human cardiac valve allografts. J Thorac Cardiovasc Surg 1996; 112: 281-286.
59. Johnson DL, Rose ML, Yacoub MH. Immunogenicity of human heart valve endothelial cells and fibroblasts. Transplant Proc 1997; 29: 984-985.
60. Hawkins JA, Breinholt JP, Lambert LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 2000; 119: 324-330.
61. Shaddy RE, Hunter DD, Osborn KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation 1996; 94: 1063-1067.
62. Hoekstra FM, Witvliet M, Knoop CY, et al. Immunogenic human leukocyte antigen class II antigens on human cardiac valves induce specific alloantibodies. Ann Thorac Surg 1998; 66: 2022-2026.
63. Hogan P, Duplock L, Green M, et al. Human aortic valve allografts elicit a donor-specific immune response. J Thorac Cardiovasc Surg 1996; 112: 1260-1266; discussion 1266-1267.
64. Smith JD, Ogino H, Hunt D, Laylor RM, Rose ML, Yacoub MH. Humoral immune response to human aortic valve homografts. Ann Thorac Surg 1995; 60: S127-S130.
65. Raanani E, Yau TM, David TE, Dellgren G, Sonnenberg BD, Omran A. Risk factors for late pulmonary homograft stenosis after the Ross procedure. Ann Thorac Surg 2000; 70: 1953-1957.
66. Yacoub MH, Suitters A, Khaghani A, Rose ML. Localisation of major histocompatibility complex antigens in aortic homograft. In: Bodnar E, Yacoub, MH, editors. Biologic and bioprosthetic valves. Proceedings of the Third International Symposium. New York: Yorke Medical Books, 1986: 63-72.
67. Moustapha A, Ross DB, Bittira B, et al. Aortic valve grafts in the rat: Evidence for rejection. J Thorac Cardiovasc Surg 1997; 114: 891-902.
68. Legare JF, Lee TD, Creaser K, Ross DB. T lymphocytes mediate leaflet destruction and allograft aortic valve failure in rats. Ann Thorac Surg 2000; 70: 1238-1245.
69. Legare JF, Ross DB, Issekutz TB, et al. Prevention of allograft heart valve failure in a rat model. J Thorac Cardiovasc Surg 2001; 122: 310-317.
70. Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999; 1: 334-342.
71. Hansen JA, Petersdorf E, Martin PJ, Anasetti C. Hematopoietic stem cell transplants from unrelated donors. Immunol Rev 1997; 157: 141-151.
72. Wiesneth M, Hertenstein B, Bunjes D, et al. ABO-incompatible bone marrow transplantation. Beitr Infusionsther 1992; 30: 354-358.
73. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfus Med 2001; 11: 325-342.
74. Yamamoto FI, Clausen H, White T, et al. Molecular genetic basis of the histo-blood group ABO system. Nature 1990; 345: 229-233.
75. Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion 1998; 38: 975-988.
76. Yankah AC, Wottge HU, Muller-Hermelink HK, et al. Transplantation of aortic and pulmonary allografts, enhanced viability of endothelial cells by cryopreservation, importance of histocompatibility. J Card Surg 1987; 2: 209-220.
77. Jaffe EA. Endothelial cells and the biology of factor VIII. N Engl J Med 1977; 296: 377-383.
78. Ketheesan N, Tay GK, Witt CS, Christiansen FT, Taylor RR, Dawkins RL. The significance of HLA matching in cardiac transplantation. J Heart Lung Transplant 1999; 18: 226-230.
79. Yankah AC, Alexi-Meskhishvili V, Weng Y, Schorn K, Lange PE, Hetzer R. Accelerated degeneration of allografts in the first two years of life. Ann Thorac Surg 1995; 60: S71-S76; discussion S76-S77.
80. Ward KE, Elkins RC, Overholt ED, et al. Evaluation of cryopreserved homografts in the right ventricular outflow tract after the Ross procedure: Intermediate-term follow up. J Heart Valve Dis 1997; 6: 130-133.
81. Shaddy RE, Tani LY, Sturtevant JE, Lambert LM, McGough EC. Effects of homograft blood type and anatomic type on stenosis, regurgitation and calcium in homografts in the pulmonary position. Am J Cardiol 1992; 70: 392-393.
82. Cleveland DC, Williams WG, Razzouk AJ, et al. Failure of cryopreserved homograft valved conduits in the pulmonary circulation. Circulation 1992; 86: II150-II153.
83. Kadner A, Chen RH, Mitchell RN, Adams DH. Homograft crossmatching is unnecessary due to the absence of blood group antigens. Ann Thorac Surg 2001; 71: S349-S352.
84. Fischlein T, Schutz A, Houshofer M, et al. Immunologic reaction and viability of cryopreserved homografts. Ann Thorac Surg 1995; 60: S122-S125; discussion S125-S126.
85. Klein J, Sato A. The HLA system: First of two parts. N Engl J Med 2000; 343: 702-709.
86. McCluskey J, Peh CA. The human leucocyte antigens and clinical medicine: An overview. Rev Immunogenet 1999; 1: 3-20.
87. Smith JD, Horninck PI, Rasmi N, Rose ML, Yacoub MH. Effect of HLA mismatching and antibody status on "homovital" aortic valve homograft performance. Ann Thorac Surg 1998; 66: S212-S215.
88. Bechtel JF, Bartels C, Schmidtke C, et al. Does histocompatibility affect homograft valve function after the Ross procedure? Circulation 2001; 104: 125-128.
89. Yankah AC, Wottge HU, Muller-Ruchholtz W. Short-course cyclosporin A therapy for definite allograft valve survival immunosuppression in allograft valve operations. Ann Thorac Surg 1995; 60: S146-S150.
90. Al-Halees Z, Pieters F, Qadoura F, Shahid M, Al-Amri M, Al-Fadley F. The Ross procedure is the procedure of choice for congenital aortic valve disease. J Thorac Cardiovasc Surg 2002; 123: 437-441; discussion 441-442.
91. Bechtel JF, Muller-Steinhardt M, Schmidtke C, Brunswik A, Stierle U, Sievers HH. Evaluation of the decellularized pulmonary valve homograft (SynerGraft). J Heart Valve Dis 2003; 12: 734-739; discussion 739-740.
92. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg 2003; 23: 1002-1006; discussion 1006.
93. Zeltinger J, Landeen LK, Alexander HG, Kidd ID, Sibanda B. Development and characterization of tissue-engineered aortic valves. Tissue Eng 2001; 7: 9-22.